BioVie Inc Aktie News

Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Thursday that two abstracts highlighting research on its lead drug candidate bezisterim (NE3107) have been accepted for presentation at the 2026 American College of Psychiatrists annual meeting in Bonita Springs, Florida. The abstracts, which focus on bezisterim's potential in Alzheimer's disease and Long COVID, will be presented as posters on Febr...

In biotech, the most compelling investment stories often emerge where medical need, scientific differentiation, and timing intersect. BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW), a clinical-stage biopharmaceutical company with a market capitalization still measured in the tens of millions, is attempting exactly that by targeting what it believes is a root driver of neurodegeneration rather than mere...

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed enrolment in a closely watched mid-stage trial testing whether its experimental drug bezisterim can slow the progression of early Parkinson's disease, putting the group on track for key data later this year. The Phase 2 study, known as SUNRISE-PD, has enrolled 60 patients who were diagnosed within the past four years and have not yet been tre...

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioVie Inc. (NASDAQ: BIVI) breached their fiduciary duties to shareholders.

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) CEO Cuong Do talked with Proactive about the company's recent developments in its two lead drug candidates: Bezisterim and BIV201. Bezisterim, which blocks TNF alpha to reduce inflammation, is being trialed in Parkinson's disease, long COVID, and Alzheimer's.

BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease Transcript

CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on December 9, 2025, at 4:15 p.m. ET.